Interpace, Affirma, and Thyroseq Performance Characteristics in 341 Bethesda Category III/IV Thyroid Nodules

被引：0
|
作者：
Connelly, C. F. [1 ]
Cimic, A. [2 ]
Baskota, S. [2 ]
机构：
[1] Columbia Univ, Irving Med Ctr, New York Presbyterian, New York, NY USA
[2] Columbia Univ, Irving Med Ctr, New York, NY USA
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2023年 / 160卷
关键词：
D O I：
10.1093/ajcp/aqad150.051
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
aqad150.05
引用
收藏
页码：S23 / S24
页数：2
相关论文
共 50 条
  • [41] Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate:An institutional experience
    Almahari, Sayed Ali
    Harb, Zainab
    Alshaikh, Safa
    CYTOJOURNAL, 2019, 16
  • [42] Thyroid cancer detection rate and associated risk factors in patients with thyroid nodules classified as Bethesda category III
    Mileva, Magdalena
    Stoilovska, Bojana
    Jovanovska, Anamarija
    Ugrinska, Ana
    Petrushevska, Gordana
    Kostadinova-Kunovska, Slavica
    Miladinova, Daniela
    Majstorov, Venjamin
    RADIOLOGY AND ONCOLOGY, 2018, 52 (04) : 370 - 376
  • [43] Utility of intraoperative frozen section analysis on Bethesda category III-IV-V thyroid nodules and the effect of concurrent imprint cytology
    Hacihasanoglu, E.
    Ozkan, F.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S249 - S249
  • [44] Serum cholesterol levels are inversely associated with the risk of malignancy in subjects with Bethesda category IV thyroid nodules
    Montejo-Marcos, Beatriz
    Lopez-Plasencia, Yaiza
    Marrero-Arencibia, Dunia
    Rodriguez-Perez, Carlos A.
    Boronat, Mauro
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2024, 71 (06): : 246 - 252
  • [45] Diagnostic accuracy of Afirma gene expression classifier, Afirma gene sequencing classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis
    Vardarli, Irfan
    Tan, Susanne
    Goerges, Rainer
    Kraemer, Bernhard K.
    Herrmann, Ken
    Brochhausen, Christoph
    ENDOCRINE CONNECTIONS, 2024, 13 (07)
  • [46] Performance of the Afirma Genomic Sequencing Classifier versus Gene Expression Classifier in Bethesda Category III Thyroid Nodules: An Institutional Experience
    Zhang, Lin
    Smola, Brian
    Cantley, Richard
    Lew, Madelyn
    Pang, Judy
    Jing, Xin
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 283 - 283
  • [47] Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience
    Zhang, Lin
    Smola, Brian
    Lew, Madelyn
    Pang, Judy
    Cantley, Richard
    Pantanowitz, Liron
    Heider, Amer
    Jing, Xin
    DIAGNOSTIC CYTOPATHOLOGY, 2021, 49 (08) : 921 - 927
  • [48] Performance of the Afirma Genomic Sequencing Classifier versus Gene Expression Classifier in Bethesda Category III Thyroid Nodules: An Institutional Experience
    Zhang, Lin
    Smola, Brian
    Cantley, Richard
    Lew, Madelyn
    Pang, Judy
    Jing, Xin
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 283 - 283
  • [49] Comments on "diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda category III in an endemic region"
    Goel, Archit
    Kapatia, Gargi
    Gupta, Shruti
    Gupta, Vikasdeep
    Sidana, Shivani
    DIAGNOSTIC CYTOPATHOLOGY, 2024, 52 (05) : 288 - 289
  • [50] Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hürthle cell cytology Discussion
    Sippel, Rebecca
    Raghunathan, Rajam
    Zeiger, Martha
    Mchenry, Christopher
    SURGERY, 2024, 175 (01) : 227 - 227
12345